Y.D. More Investments Ltd Trims Stock Position in Veeva Systems Inc. $VEEV

Y.D. More Investments Ltd decreased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 35.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 20,973 shares of the technology company’s stock after selling 11,695 shares during the quarter. Y.D. More Investments Ltd’s holdings in Veeva Systems were worth $6,040,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Veeva Systems in the 1st quarter valued at about $365,684,000. Price T Rowe Associates Inc. MD lifted its stake in Veeva Systems by 20.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after buying an additional 689,700 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Veeva Systems by 423.8% in the second quarter. Los Angeles Capital Management LLC now owns 841,303 shares of the technology company’s stock valued at $242,278,000 after acquiring an additional 680,702 shares during the period. Linonia Partnership LP grew its position in shares of Veeva Systems by 52.7% during the first quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after acquiring an additional 633,585 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Veeva Systems by 48.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock valued at $416,918,000 after purchasing an additional 585,785 shares during the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems Stock Performance

NYSE:VEEV opened at $293.24 on Friday. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The stock has a fifty day moving average price of $288.89 and a two-hundred day moving average price of $277.67. The stock has a market capitalization of $48.06 billion, a price-to-earnings ratio of 60.21, a PEG ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. During the same quarter in the previous year, the firm posted $1.62 earnings per share. Veeva Systems’s revenue for the quarter was up 16.7% on a year-over-year basis. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, analysts predict that Veeva Systems Inc. will post 4.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Stifel Nicolaus raised their price objective on shares of Veeva Systems from $295.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Raymond James Financial reissued an “outperform” rating and set a $340.00 price target (up previously from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Wall Street Zen downgraded Veeva Systems from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer reaffirmed an “outperform” rating and set a $325.00 price objective on shares of Veeva Systems in a research report on Thursday, August 28th. Finally, Wells Fargo & Company boosted their target price on Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a report on Tuesday, August 26th. Seventeen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $307.28.

Insider Buying and Selling

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. This represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas D. Schwenger sold 3,350 shares of Veeva Systems stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 24,665 shares of company stock valued at $7,438,000. Corporate insiders own 10.30% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.